Mazdutide
Also known as · IBI362 · LY3305677
to clear
How a single dose clears, assuming first-order elimination. The half-life is the biggest driver of how often you dose — start a cycle to see your own cumulative concentration curve.
An investigational GLP-1/glucagon dual agonist (an oxyntomodulin analog) studied for obesity and diabetes.
Dual GLP-1/glucagon receptor agonism for appetite control plus increased energy expenditure.
Weekly subQ; trial titration up to ~9 mg.
Refrigerated; protect from light.
This page summarizes publicly available information. None of it constitutes medical advice, prescription, or recommendation to acquire, possess, or use any compound. Many peptides described are research chemicals not approved for human use in the EU. Consult a licensed physician.
Semaglutide
A long-acting GLP-1 receptor agonist for type-2 diabetes and weight management. Slows gastric emptying and suppresses appetite.
Tirzepatide
A dual GIP/GLP-1 receptor agonist with superior weight loss and glycemic control versus semaglutide in head-to-head trials.
Retatrutide
An investigational triple agonist (GIP/GLP-1/glucagon) showing the largest weight-loss figures yet in trials. Not yet approved.